HER2 Type Male Breast Cancer Successfully Treated with Pertuzumab, Trastuzumab, and Eribulin Therapy: A Case Report
- 1 Department of Breast Disease Center, Asahikawa Medical University, Asahikawa, Japan
- 2 Department of Breast Disease Center, Asahikawa Medical University, Asahikawa, Japan
- 3 Department of Breast Disease Center, Asahikawa Medical University, Asahikawa, Japan
- 4 Department of Breast Disease Center, Asahikawa Medical University, Asahikawa, Japan
- 5 Department of Breast Disease Center, Asahikawa Medical University, Asahikawa, Japan
- 6 Department of Breast Disease Center, Asahikawa Medical University, Asahikawa, Japan
Abstract
Background : Male breast cancer is rare, accounting for approximately 0.5% - 1.0% of all breast cancer cases; hormone-dependent luminal type male breast cancer is the most common. The proportion of hormone receptor-negative an d human epithelial growth factor Receptor type 2 -positive breast cancer is extremely low among male breast cancer. A patient with advanced HER2 type b reast cancer, a rare male breast cancer, was successfully treated with pert uzumab, trastuzumab, and eribulin therapy. Case Presentation : A 75- year-old man presented to our hospital with induration of the right anterior chest and lymphoedema of the right upper limb. Based on the results of core needle biopsy, he was diagnosed with HER2 type invasive ductal carcinoma associated with bone metastasis (stage IV). Chemotherapy with pertuzumab, trastuzumab, and eribulin was started. The drugs were remarkably effective, and his lymphoedema tended to improve. Conclusion : We reported a successful case of chemotherapy and targeted therapy for a rare male breast cancer of HER2 positive and hormone negative type.
- Leone, J.P., Leone, J., Zwenger, A.O., Iturbe, J., Vallejo, C.T. and Leone, B.A. (2015) Prognostic significance of tumor subtypes in male breast cancer: a population-based study. Breast Cancer Research and Treatment, 152, 601-609. https://doi.org/10.1007/s10549-015-3488-y
- Masci, G., Caruso, M., Caruso, F., Salvini, P., Carnaghi, C., Giordano, L., Miserocchi, V., Losurdo, A., Zuradelli, M., Torrisi, R., Di Tommaso, L., Tinterri, C., Testori, A., Garcia-Etienne, C.A., Gatzemeier, W. and Santoro, A. (2015) Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series. Oncologist, 20, 586-592. https://doi.org/10.1634/theoncologist.2014-0243
- Chavez-Macgregor, M., Clarke, C.A., Lichtensztajn, D., Hortobagyi, G.N. and Giordano, S.H. (2013) Male Breast Cancer According to Tumor Subtype and Race: A Population-Based Study. Cancer, 119, 1611-1617. https://doi.org/10.1002/cncr.27905
- Abreu, M.H., Afonso, N., Abreu, P.H., Menezes, F., Lopes, P., Henrique, R., Pereira, D. and Lopes, C. (2016) Male Breast Cancer: Looking for Better Prognostic Subgroups. The Breast, 26, 18-24. https://doi.org/10.1016/j.breast.2015.12.001
- Baselga, J., Cortés, J., Kim, S.B., Im, S.A., Hegg, R., Im, Y.H., Roman, L., Pedrini, J.L., Pienkowski, T., Knott, A., Clark, E., Benyunes, M.C., Ross, G. and Swain, S.M. (2012) CLEOPATRA Study Group. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. The New England Journal of Medicine, 366, 109-111. https://doi.org/10.1056/NEaJMoa1113216
- Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Bhattacharyya, G., et al. (2017) 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). The Breast, 31, 244-259. https://doi.org/10.1016/j.breast.2017.01.001
- Narui, K., Yamashita, T., Kitada, M., Kawaguchi, H., Hattori, M., et al. (2017) Eribulin in Combination with Pertuzumab plus Trastuzumab for HER2-Positive Advanced or Recurrent Breast Cancer (JBCRG-M03). Journal of Clinical Oncology, 35, 1025-1025. https://doi.org/10.1200/JCO.2017.35.15_suppl.1025
- Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J.L., Vahdat, L.T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., Vladimirov, V., Cardoso, F., Koh, H., Bougnoux, P., Dutcus, C.E., Seegobin, S., Mir, D., Meneses, N., Wanders, J. and Twelves, C. (2011) EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) Investigators. Eribulin Monotherapy versus Treatment of Physician’s Choice in Patients with Metastatic Breast Cancer (EMBRACE): A Phase 3 Open-Label Randomised Study. Lancet, 377, 914-923. https://doi.org/10.1016/S0140-6736(11)60070-6